Search results for "Non-alcoholic fatty liver disease"

showing 10 items of 266 documents

"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".

2022

Objectives Non-alcoholic fatty liver disease (NAFLD) is strongly associated with cardiovascular disease in the general population. We aimed to assess the impact of NAFLD and liver fibrosis on intermediate-high cardiovascular risk in people living with HIV. Methods We included people living with HIV from three cohorts. NAFLD and significant liver fibrosis were defined using transient elastography: controlled attenuation parameter >= 288 dB/m and liver stiffness measurement >= 7.1 kPa, respectively. Cardiovascular risk was assessed with the atherosclerotic cardiovascular disease (ASCVD) risk estimator in patients aged between 40 and 75 years and categorised as low if <5%, borderline …

AdultLiver CirrhosisLiver CirrhosiHIV InfectionsBMIElasticity Imaging TechniqueNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseHumansHIV InfectionPharmacology (medical)Prospective StudiesNon-alcoholic Fatty Liver Disease.AgedASCVD score; BMI; controlled attenuation parameter; HIV mono-infection; transient elastographyASCVD scoreRisk FactorHealth PolicyHIV mono-infectionHeart Disease Risk FactorMiddle Agedtransient elastographycontrolled attenuation parameterProspective StudieInfectious DiseasesLiverCardiovascular DiseasesHeart Disease Risk FactorsElasticity Imaging TechniquesHumanHIV medicineREFERENCES
researchProduct

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

2018

AbstractLiver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non-invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum microRNA biomarkers with altered levels in NAFLD patients. In the present study, we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort. Moreover, miR-192, -27b, -22, -197 and -30c appeared specific for NAFLD, when compared wi…

AdultLiver CirrhosisMale0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineSeverity of Illness Indexdigestive systemArticleCohort Studies03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicinemicroRNANonalcoholic fatty liver diseasemedicineHumansCirculating MicroRNAlcsh:ScienceSerum micrornaAgedLiver injuryMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RLiquid BiopsyMiddle AgedPrognosismedicine.diseasedigestive system diseasesCirculating MicroRNA030104 developmental biologyLiverLiver biopsyCohortDisease ProgressionFemalelcsh:QbusinessBiomarkers
researchProduct

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

2018

Background & Aims The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. Methods We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fi…

AdultLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtysteatohepatitisSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineHumansMedicineIn patientProspective StudiesKeratin-18Hepatologymedicine.diagnostic_testbusiness.industryFatty liverExternal validationReproducibility of ResultsMiddle Agedmedicine.disease3. Good health030104 developmental biologyItalyLiverROC Curvenon-invasive markerLiver biopsyCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatohepatitisfibrosibusinessAlgorithmsBiomarkersLiver International
researchProduct

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease

2019

Background & Aims Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron‐overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Methods We selected 468 patients with biopsy‐proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial c…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadBiopsyGastroenterologyhistology03 medical and health sciencesLiver diseaseiron0302 clinical medicineFibrosisInternal medicinemedicineHumansRetrospective StudiesMetabolic SyndromeHepatologymedicine.diagnostic_testbiologybusiness.industryferritinFatty livernon-alcoholic fatty liver diseaseMononuclear phagocyte systemMiddle Agedmedicine.diseaseFerritinLogistic ModelsLiver030220 oncology & carcinogenesisLiver biopsyFerritinsDisease Progressionbiology.proteinFemale030211 gastroenterology & hepatologyAlcoholic fatty liverferritin; histology; iron; non-alcoholic fatty liver diseaseSteatohepatitisbusinessLiver International
researchProduct

Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

2017

SummaryBackground The accuracy of available non-invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still limited. Aim To assess the diagnostic performance of paired or serial combination of non-invasive tools in NAFLD patients. Methods We analysed data from 741 patients with a histological diagnosis of NAFLD. The GGT/PLT, APRI, AST/ALT, BARD, FIB-4, and NAFLD Fibrosis Score (NFS) scores were calculated according to published algorithms. Liver stiffness measurement (LSM) was performed by FibroScan. Results LSM, NFS and FIB-4 were the best non-invasive tools for staging F3-F4 fibrosis (AUC 0.863, 0.774, and 0.792, respectively), with LSM ha…

AdultLiver CirrhosisMalemedicine.medical_specialtyLiver fibrosisDiagnostic accuracySensitivity and SpecificityGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseLiver stiffnessFibrosisInternal medicineHistological diagnosisNonalcoholic fatty liver diseasemedicineHumansPharmacology (medical)In patientAgedHepatologybusiness.industryNon invasiveGastroenterologyMiddle Agedmedicine.disease030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologybusinessAlgorithmsAlimentary Pharmacology & Therapeutics
researchProduct

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in pat…

2014

Background & Aims The accuracy of noninvasive tools for the diagnosis of severe fibrosis in patients with nonalcoholic fatty liver disease(NAFLD) in clinical practice is still limited. We aimed at assessing the diagnostic performance of combined noninvasive tools in two independent cohorts of Italian NAFLD patients. Methods We analysed data from 321 Italian patients(179 Sicilian-training cohort, and 142 northern Italy-validation cohort) with an histological diagnosis of NAFLD. Severe fibrosis was defined as fibrosis ≥ F3 according to Kleiner classification. The APRI, AST/ALT, BARD, FIB-4, and NFS scores were calculated according to published algorithms. Liver stiffness measurement(LSM) was …

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyAdolescentLSM ; NAFLD ; NFSBiopsySettore MED/08 - Anatomia PatologicaGastroenterologySeverity of Illness IndexLSM; NAFLD; NFS; Adolescent; Adult; Aged; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Biopsy; Female; Humans; Italy; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Young Adult; Severity of Illness Index; Hepatology; Medicine (all)Young AdultFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDNonalcoholic fatty liver diseaseSeverity of illnessBiopsyNFSmedicineHumansLSMAspartate AminotransferasesAgedRetrospective StudiesSettore MED/12 - Gastroenterologiabiologymedicine.diagnostic_testHepatologybusiness.industryMedicine (all)Retrospective cohort studyAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseAlanine transaminaseItalyLiverArea Under CurveCohortbiology.proteinFemalebusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)

2019

PurposeTo investigate the performance of MR-based texture analysis (TA) for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).MethodsFifty-four adult patients (33 females, 21 males, mean age 49.813.5years) with biopsy-proven NAFLD were enrolled and underwent MR imaging on a 1.5T system. TA parameters were extracted on axial noncontrast 3D-GRE T1W images (slice thickness=4.6mm) using a commercially available research software (TexRAD). Receiver operating curves (ROC), areas under the ROC (AUROC) and 95% confidence intervals (CI) were calculated to assess the accuracy of each TA parameter for the diagnosis of significant (F2) and advanced fibrosis (F…

AdultLiver CirrhosisMalemedicine.medical_specialtyUrologyGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciencesImaging Three-Dimensional0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineImage Interpretation Computer-AssistedNonalcoholic fatty liver diseaseHumansNonalcoholic fatty liver diseaseMedicineRadiology Nuclear Medicine and imagingIn patientTexture analysiAgedRetrospective StudiesRank correlationRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryGastroenterologyMagnetic resonance imagingMiddle AgedHepatologymedicine.diseaseMagnetic Resonance ImagingConfidence intervalLiverMagnetic resonance030220 oncology & carcinogenesisElasticity Imaging TechniquesFemaleSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessHepatic fibrosisHepatic fibrosisSoftwareAbdominal Radiology
researchProduct